Research programme: BACE1 protein inhibitors - Merck and Co

Drug Profile

Research programme: BACE1 protein inhibitors - Merck and Co

Alternative Names: SCH-1359113; SCH-1682496; SCH-785532

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co; Sunesis Pharmaceuticals
  • Developer Merck & Co
  • Class Guanidines; Hydantoins; Macrocyclic compounds; Piperidines; Pyrimidinones; Small molecules; Sulfones
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
  • 10 Apr 2008 Research phase development is ongoing
  • 21 Jul 2006 Data presented at the 10th International Conference on Alzheimer's Disease and Related Disorders (ICAD-2006) have been added to the Alzheimer's Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top